Analyst Update: GameStop, State Street, Portola Pharma

Analysts adjusted their ratings and price targets on GameStop Corp. (NYSE:GME), State Street Corp (NYSE:STT), and Portola Pharmaceuticals Inc (NASDAQ:PTLA)

Josh Selway

Mar 28, 2016 at 3:07 PM

Analysts are weighing in on video game retailer GameStop Corp. (NYSE:GME), investment firm State Street Corp (NYSE:STT), and drugmaker Portola Pharmaceuticals Inc (NASDAQ:PTLA). Here's a quick roundup of today's brokerage notes on GME, STT, and PTLA.

After falling to as low as $28.40 out of the gate, GME has bounced back to gain 0.2% at $30.32 -- though the stock is stalling out at its 20-day moving average. Late Thursday, GME said fourth-quarter profit beat expectations, yet current-quarter and full-year guidance disappointed. Wedbush has since lowered its price target to $36 from $38, while Benchmark trimmed its target to $26.33 from $27.36. Most of Wall Street is skeptical of GameStop Corp. Eight of the 13 brokerages that cover GME call it a "hold" or "strong sell," while over 38% of the stock's float is sold short.

STT is down 0.5% at $58.48, following a downgrade to "underperform" from "market perform" at KBW. The stock is now 11.9% lower in 2016, and option traders have taken a bearish stance amid in recent weeks. For example, during the past 10 days at the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), State Street Corp has accumulated a call/put volume ratio of 5.58, which tops 70% of similar readings from the past year.

As expected, negative analyst attention is putting pressure on PTLA. The stock is down 6.6% at $18.94, after Goldman Sachs cut its opinion to "neutral" from "buy," slashed its price target to $30 from $65, and removed the stock from its "America's Buy" list. The shares have dropped over 63% year-to-date, earlier touching a two-year low of $18.20. However, Portola Pharmaceuticals Inc's recent sell-off has left it in oversold territory, with the stock's 14-day Relative Strength Index (RSI) coming in at 26, meaning a short-term bounce is theoretically a possibility.

For other stocks in analysts' crosshairs, read Analyst Upgrades: Finish Line Inc, Medivation Inc, and McDonald's Corporation and Analyst Downgrades: QUALCOMM, Inc., Atwood Oceanics, Inc., and Transocean LTD.

Follow @Schaeffers

$40 Gets You 4 High-Conviction Trades. Let's Go.

We just booked back-to-back double-digit gains on Celsius and Palantir in Trade of the Week, and we’re eyeing even bigger wins!

Every week starts with a fully defined options trade straight from the desk Schaeffer’s Senior V.P. of Research, Todd Salamone, backed by 30+ years of proven market experience and disciplined risk management.

Right now, you can get 4 total trades over the next 4 weeks for $40 – just $10 per trade.

👉 Sign Up Now to Receive Your First Trade!